GEN News

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.